Related Experiment Videos
Modulation of insulin secretion by diazepam binding inhibitor and its processing products
P Borboni1, L Condorelli, P De Stefanis
1Department of Internal Medicine-Endocrinology, II University of Rome Tor Vergata, Italy.
Neuropharmacology
|December 1, 1991
Summary
Diazepam binding inhibitor (DBI) and octadecaneuropeptide (ODN) reduce glucose-stimulated insulin secretion from pancreatic islets. These peptides may modulate insulin release via a paracrine mechanism, impacting glucose metabolism.
Area of Science:
- Endocrinology
- Molecular Biology
- Cell Biology
Background:
- Diazepam binding inhibitor (DBI) is found in pancreatic islet delta cells.
- The role of DBI and its fragments in insulin secretion is not fully understood.
Purpose of the Study:
- To investigate the effects of DBI and its synthetic fragments on glucose-stimulated insulin secretion.
- To explore the potential paracrine mechanisms involved in insulin regulation.
Main Methods:
- Isolated rat pancreatic islets were used for static incubation and perifusion experiments.
- The study examined the impact of DBI and its fragments (ODN, TTN, DBI42-50, DBI53-62) on insulin release under varying glucose concentrations.
- Immunoreactivity for DBI and ODN in pancreatic islets was assessed.
Main Results:
- DBI and ODN significantly reduced insulin secretion induced by high glucose (16.7 mM) at concentrations of 1-10 nM.
- Neither DBI nor ODN affected insulin secretion under basal glucose conditions (2.8 mM).
- TTN, DBI42-50, and DBI53-62 did not influence insulin secretion under either basal or stimulated conditions.
Conclusions:
- DBI and its processing product ODN can modulate glucose-stimulated insulin secretion.
- These peptides may exert their effects through a paracrine mechanism within the pancreatic islets.
- The findings suggest a novel regulatory pathway for insulin release involving DBI and ODN.